Mar 4, 2026 08:15AM
Mar 4, 2026 08:15AM
Mar 2, 2026 07:02AM
Mar 2, 2026 07:02AM
Jan 12, 2026 06:30AM
Jan 12, 2026 06:30AM
Nov 5, 2025 06:30AM Ocugen Provides Business Update with Third Quarter 2025 Financial Results
Sep 2, 2025 07:02AM
Sep 2, 2025 07:02AM
Aug 1, 2025 08:25AM
Jul 21, 2025 07:30AM
Jul 21, 2025 07:30AM
Jul 21, 2025 07:30AM
Jun 24, 2025 06:51AM H.C. Wainwright Reiterates Buy Rating on Ocugen, Inc. (OCGN)
Jun 23, 2025 07:30AM
Jun 23, 2025 07:30AM
Jun 16, 2025 07:03AM
Jun 16, 2025 07:02AM
Jun 11, 2025 07:30AM
May 27, 2025 07:04AM
May 27, 2025 07:02AM Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease
May 9, 2025 08:01AM
Mar 5, 2025 07:02AM
Mar 3, 2025 09:01AM
Mar 3, 2025 09:00AM
Feb 27, 2025 08:48AM
Feb 27, 2025 08:46AM
Feb 12, 2025 07:45AM Ocugen (OCGN) Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to dAMD
Feb 12, 2025 07:42AM
Feb 3, 2025 06:31AM
Feb 3, 2025 06:30AM
Jan 27, 2025 06:31AM
Jan 27, 2025 06:30AM
Nov 20, 2024 07:33AM
Nov 20, 2024 07:30AM Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt
Nov 8, 2024 06:45AM
Oct 22, 2024 07:02AM
Oct 22, 2024 07:02AM
Oct 9, 2024 06:33AM
Oct 9, 2024 06:30AM
Aug 28, 2024 06:32AM
Aug 28, 2024 06:30AM Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
Aug 26, 2024 07:03AM
Aug 26, 2024 07:02AM
Aug 8, 2024 06:45AM
Aug 5, 2024 06:31AM
Aug 5, 2024 06:30AM
Jul 25, 2024 06:30AM
Jun 21, 2024 07:01AM Ocugen (OCGN) Announces Data and Safety Monitoring Board Approved Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
Jun 21, 2024 07:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All